Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

MorphoSys AG Investor Presentation 2009

Feb 13, 2009

291_ip_2009-02-13_27e88be3-a688-43e7-9274-66807b140667.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

The 11th Annual BIO CEO & Investor Conference

New York – February 9, 2009

Safe Harbour

This presentation includes forward-looking statements.

Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations and the availability of financing.

These and other risks and uncertainties are detailed in the Company's Annual Report.

C
o
m
p
a
n
y		 A
i
d
d
t
t
i
b
d
"
n
n
e
p
e
n
e
n
a
n
o
y
c
o
m
p
a
n
y
&
T
h
t
i
h
t
i
b
d
t
"
e
r
a
p
e
c
r
e
s
e
a
r
c
a
n
o
s
e
g
m
e
n
s
u
y
B
d
i
l
i
i
h
d
&
d
t
t
t
"
r
o
a
p
p
e
n
e
p
a
r
n
e
r
e
n
-p
a
r
n
e
r
e
w
u
i
i
i
d
i
i
t
p
r
o
g
r
a
m
s
n
a
r
o
s
n
c
a
o
n
s
v
u
O
i
i
t
r
g
a
n
a
o
n
z		 H
Q
M
i
i
d
(
M
i
h
)
/
D
b
i
d
i
i
i
t
"
a
r
n
s
r
e
u
n
c
s
u
s
a
r
e
s
n
,
D
ü
l
d
f
/
D
O
f
d
/
U
K
&
R
l
i
h
/
U
S
A
s
s
e
o
r
o
r
a
e
g
x
,
3
2
0
l
l
d
i
d
"
e
m
p
o
y
e
e
s
w
o
r
w
e
L
i
d
t
s
e		 f
S
F
k
t
t
k
E
h
T
D
A
X
"
r
a
n
u
r
o
c
x
c
a
n
g
e
e
c
,
A
D
R
L
l
1
"
e
e
v
T
h
l
e
c
n
o
o
g
y		 L
d
i
i
H
C
A
L
l
f
t
t
"
e
a
n
g
p
r
o
p
r
e
a
r
y
u
p
a
o
r
m
,
S
&
d
i
d
t
t
t
t
t
t
"
r
o
n
g
u
n
s
p
u
e
p
a
e
n
e
s
a
e
F
i
i
l
n
a
n
c
a
s		 P
f
i
b
l
b
l
h
t
t
t
"
r
o
a
e
s
r
o
n
g
a
a
n
c
e
s
e
e
,
K
e
y		 i
F
n
a
n
c		 i
l
a
s
In
E
U
R
i
l
l
ion
m
s		 /
/
0
9
3
0
2
0
0
8		 /
/
1
2
3
1
2
0
0
7
C
h
C
h
E
i
&
M
k
t.
S
i
t
i
a
s
a
s
q
u
v.
a
r
e
e
c
u
r
e
s
,		 1
2
7
3		 1
0
6
9
O
h
C
A
t
t
t
e
r
u
r
r
e
n
s
s
e
s		 1
4
6		 1
6
0
C
T
t
l
N
t
A
t
o
a
o
n
r
r
e
n
s
s
e
s
u
-		 5
6
9		 6
1
8
T
l
A
t
t
o
a
s
s
e
s		 1
9
8
8		 1
8
4
7
T
t
l
C
t
L
i
b
i
l
i
t
i
o
a
r
r
e
n
a
e
s
u		 2
3
6		 2
9
4
T
l
N
C
L
i
b
i
l
i
i
t
t
t
o
a
o
n
u
r
r
e
n
a
e
s
-		 1
4
9		 9
8
S
'
T
t
l
h
h
l
d
E
i
t
o
a
a
r
e
o
e
r
s
q
u
y		 1
6
0
3		 1
4
5
5
T
l
L
i
b
i
l
i
i
t
t
o
a
a
e
s		 1
9
8
8		 1
8
4
7
In
E
U
R
i
l
l
ion
m
s		 9
M
h
2
0
0
8
t
o
n
-		 9
M
h
2
0
0
7
t
o
n
-
R
e
v
e
n
u
e
s		 5
3
3		 4
4
1
T
l
O
i
E
t
t
o
a
p
e
r
a
n
g
p
e
n
s
e
s
x		 3
8
2		 3
7
2
f
i
f
i
P
O
t
t
r
o
r
o
m
p
e
r
a
o
n
s		 1
5
1		 6
9
N
a
m
e		 P
t
a
r
n
e
r		 I
d
i
i
t
n
c
a
o
n		 D
i
s
c
o
v
e
r
y		 P
l
i
i
r
e-
c
n
c		 P
h
1
a
s
e		 P
h
2
a
s
e		 P
h
3
a
s
e		 M
k
t
a
r
e
G
t
b
a
n
e
n
e
r
m
a
u
(
R
1
4
0
)
5		 R
h
o
c
e		 's
A
l
h
i
e
m
e
r
z
D
i
s
e
a
s
e
B
H
Q
8
8
0		 N
t
i
o
v
a
r
s		 C
a
n
c
e
r
d
n.		 C
t
e
n
o
c
o
r		 I
l
/
m
m
u
n
o
o
g
y
C
a
n
c
e
r		 5 5
P
d
t
a
r
n
e
r
e		 P
r
o
g
r
a
m
s
2
9
P
d
t
a
r
n
e
r
e
P
r
o
g
r
a
m
s		 V
i
a
r
o
s
u		 *
V
i
a
r
o
s
u
2
2
P
d
t
a
r
n
e
r
e
P
r
o
g
r
a
m
s		 V
i
a
r
o
s
u		 *
V
i
a
r
o
s
u
O
1
0
3
M
R		 - R
h
i
d
t
e
u
m
a
o
A
t
h
i
t
i
r
r
s
M
O
R
2
0
2		 - C
a
n
c
e
r		 i
3
P
t
r
o
p
r
e
a
r		 P
y
r
o
g
r
a
m
s
M
O
R
2
0
x		 - C
a
n
c
e
r
d
n.		 M
h
S
/
o
r
p
o
y
s
N
t
i
o
a
r
s
v		 d
n.		 1
P
D
P
r
e-
e
r
v.		 o
g
r
a
m

* Includes cancer, inflammatory, autoimmune, infectious, musculoskeletal & central nervous system diseases

Proprietary Product Pipeline: Projected Status Year-End 2009

N
a
m
e		 P
t
a
r
n
e
r		 I
d
i
i
t
n
c
a
o
n		 D
i
s
c
o
e
r
v
y		 P
l
i
i
r
e-
c
n
c		 P
h
1
a
s
e		 P
h
2
a
s
e		 P
h
3
a
s
e		 M
k
t
a
r
e
R
h
i
d
t
e
u
m
a
o
A
t
h
i
t
i
r
r
s
M
O
R
1
0
3		 - R
i
t
e
s
p
r
a
o
r
y
M
S
M
O
R
2
0
2		 - C
a
n
c
e
r
O
M
R
2
0
x		 - C
a
n
c
e
r		 U
7
t
p
o		 P
i
t
r
o
p
r
e
a
r
y
M
O
R
2
0
x		 - C
a
n
c
e
r		 P
r
o
g
r
a
m
s
M
O
R
x
x
x		 - d
n.
O
M
R
x
x
x		 - d
n.
M
O
R
x
x
x		 - d
n.
d
n.		 M
h
S
/
o
r
p
o
y
s
N
t
i
o
a
r
s
v		 d
n.		 1
P
D
r
e-
e		 P
v.
r
o
g
r
a
m
d
n.		 M
h
S
/
o
r
p
o
y
s
G
l
a
a
p
a
g
o
s		 B
&
J
i
t
o
n
e
o
n
D
i
s
e
a
s
e
s		 3
T
t
a
r
g
e
i
E
l
t
v
a
u
a
o		 i
s
n
n

Doubling of Investment in Proprietary R&D in 2009 to €18-20 million

Therapeutic Antibody Programs With Leading Pharma & Biotech Companies

55 Active Partnered Therapeutic Programs

Partnerships: Typical Terms per Program

Partnered HuCAL Antibodies in the Clinic

Gantenerumab (R1450)

  • IgG1 antibody targeting amyloid-β
  • Crosses blood-brain barrier in transgenic mouse, decreasing cerebral Aβ burden
  • Single & escalating dose Ph 1 studies in mild-to-moderate Alzheimer's patients have completed recruitment
  • Antibody behaves as expected

BHQ880

  • IgG1 antibody targeting DKK-1
  • Over-expression of DKK-1 by myeloma cells may upset osteoblast/osteoclast balance
  • Ph 1 study ongoing in the US
  • A Ph 1/2 study is planned in relapsed or refractory myeloma patients

Centocor

Antibody targeting oncology- & immunology-related target

Ph 2 trial in immunological indication started November 2008

  • HuCAL IgG1 antibody targeting GM-CSF
  • Primary indication: Rheumatoid arthritis
  • Potential in asthma, COPD, multiple sclerosis…
  • Clinical Development
  • Ph 1: 7 cohorts @ 9 volunteers in a randomized, double-blind, placebocontrolled, single-ascending dose trial
  • Safety, tolerability, pharmacokinetics, CRP
  • Q2 2009: Report Ph 1 results
  • H2 2009: File for Ph 1b/2a trial
  • MOR103 Advantages
  • Femtomolar affinity: potential CoGS advantage
  • Strong IP Position
    • Exclusive license to US patent covering inhibitors of GM-CSF in inflammatory conditions
    • Patent applications on the MOR103 antibody family

MOR202: Proprietary Cancer Program

  • MOR202, a fully human IgG1 HuCAL antibody, targeting CD38, a 45 kDa ectoenzyme heavily over-expressed in 95% of MM cell-lines and some leukemia lines
  • Primary indication: Multiple myeloma (MM)
  • Function: Induces cell-killing by ADCC, CDC & apoptosis
  • Commercial Opportunity
  • 10 of hematological cancer / 1% of all cancer / 2% of cancer deaths
  • No curative therapies
  • Median survival 24 30 months, all patients eventually relapse
  • Development Timeline
  • Q1 2008: Development candidate selected, start of process development
  • 2009: Toxicology & safety, manufacturing

AbD Serotec: Gaining Scale

Guidance

€
I
i
l
l
i
n
m
o
n
s		 E
*
2
0
0
8		 A
2
0
0
7
T
l
G
R
t
o
a
r
o
u
p
e
v
e
n
u
e
s		 7
3
7
6
–		 6
2
G
O
i
P
f
i
t
t
r
o
p
p
e
r
a
n
g
r
o
u		 1
5
1
6
–		 0
7

2008

  • Revenue split therapeutics : research products = ca. 75 : 25
  • Expenses include proprietary R&D spend of € 9 million

2009

  • Proprietary R&D spend will double, to € 18 – 20 million
  • Maintain profitability

Outlook

  • Aiming for 10-20% annual revenue growth
  • Maintain profitability, while strengthening pipeline

* Estimated numbers

P
&
L		 O
€
4
0
0
i
f
d
t
"
v
e
r
m
n
u
u
r
e
r
e
v
e
n
u
e
a
s
s
u
r
e
L
i
i
l
&
l
i
d
t
t
t
"
u
c
r
a
v
e
m
e
s
o
n
e
r
o
y
a
y
u
p
s
e
S
f
f
t
h
l
d
d
l
t
"
r
o
n
g
c
a
s
o
w
u
n
s
o
w
n
e
v
e
o
p
m
e
n
-
S
B
l
h
t
a
a
n
c
e
e
e		 O
€
1
2
h
5
"
v
e
r
m
c
a
s
A
i
i
i
h
t
t
t
t
t
t
"
c
q
u
s
o
n
s
o
s
u
p
p
o
r
g
r
o
w
s
r
a
e
g
y
i
B
u
s
n
e
s
s		 A
i
b
d
i
i
f
l
l
f
t
t
"
n
o
e
s
c
o
m
p
r
s
e
m
o
s
s
u
c
c
e
s
s
u
c
a
s
s
o
b
i
h
i
l
t
o
p
a
r
m
a
c
e
u
c
a
s
P
i
l
i
p
e
n
e		 C
5
9
H
A
L
t
h
t
i
i
"
u
e
r
a
p
e
u
c
p
r
o
g
r
a
m
s
o
n
g
o
n
g
M
l
t
i
l
t
d
i
d
i
t
i
"
p
e
p
a
r
n
e
r
s
a
n
n
c
a
o
n
s
u
F
h
i
t
o
r
c
o
m
n
g
N
f
l
e
w
s
o
w
-		 &
F
b
2
6
2
0
0
8
l
t
2
0
0
9
i
d
"
e
r
e
s
s
g
a
n
c
e
:
u
u
Q
2
2
0
0
9
R
l
f
M
O
R
1
0
3
P
h
1
d
t
t
"
e
s
s
r
o
m
s
:
u
u
y
H
2
2
0
0
9
S
M
O
R
1
0
3
P
h
1
b
/
2
d
t
t
t
"
:
a
r
a
s
u
y
N
I
N
D
i
l
i
t
"
e
w
p
a
r
n
e
r
s
p
p
e
n
e
p
r
o
g
r
e
s
s
,

Thank You

www.morphosys.com

Dr. Simon Moroney

Chief Executive Officer

Phone +49 (0)89 / 899 27-311 Fax +49 (0)89 / 899 27-5311 Email [email protected]

Dr. Claudia Gutjahr-Löser

Head of Corp. Comm. & IR

Phone +49 (0)89 / 899 27-122 Fax +49 (0)89 / 899 27-5122 Email [email protected]

More from MorphoSys AG

AGM Information 2024
Aug 27
Delisting Announcement 2024
Aug 5
AGM Information 2024
Jul 19
AGM Information 2024
Jul 19
Declaration of Voting Results & Voting Rights Announcements 2024
Jul 18
Delisting Announcement 2024
Jul 12
Legal Proceedings Report 2024
Jul 12
Report Publication Announcement 2024
Jul 5
Major Shareholding Notification 2024
Jul 2
Declaration of Voting Results & Voting Rights Announcements 2024
Jun 21
View all filings →